drugset / Trial / NCT06071962

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain

NCT06071962 ↗

Phase 3 Unknown 558 enrolled Apurano Pharmaceuticals GmbH
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates the long term efficacy and tolerability of the THC-focused nano endocannabinoid system modulator AP707 in patients with chronic back pain disorders. Patients receive AP707 or placebo over the course of 14 weeks as an add-on to the standard of care. Changes in pain intensity, quality of life and sleep and others measures are monitored through different scales to assess the efficacy of AP707 in patients with chronic back pain.

Timeline

Start
2023-11-02
Primary completion
2024-09-30
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Adezunap Other / unclassified 17.6 mg Other

Indications